Cell Therapeutics (CTIC +0.9%) gains after the company receives a Notice of Allowance from the U.S. Patent and Trademark Office for an application directed to increasing the plasma half-life of therapeutic proteins and peptides by recombinantly conjugating them to a unique, non-immunogenic peptide repeat sequence.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs